UCB announced that BIMZELX (bimekizumab-bkzx) is commercially available for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. BIMZELX was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2023. BIMZELX is available as an autoinjector and a pre-filled syringe.

BIMZELX may be administered subcutaneously by a healthcare professional, or a patient may self-inject after proper training. People living with moderate-to- severe plaque psoriasis should talk to their healthcare provider to see if BIMZELX may been right for them. BIMZELX are the first and only approved psoriasis treatment designed to selectively inhibit two key cytokines driving inflammatory processes - interleukin 17A (IL-17A) and interleukin 17F (IL-17F).

The approval of BIMZELX is supported by data from three Phase 3, multicenter, randomized, placebo and/or active comparator-controlled trials (BE READY, BE VIVID, and BE SURE), which evaluated the efficacy and safety of BIMZELX in 1,480 adults with moderate-to-severe plaque Psoriasis. Through BIMZELX Navigate, UCB offers tailored patient support to all those with moderate-to-severe ploriasis upon receiving their BIMZELX prescription. While work toward securing access for patients with payer organizations, BIMZELX Navigation program is in place and successfully operating to get patients started.